# Fate Therapeutics Inc.

**FATE**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001434316


# None

### No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


| Scoreboard | |
|---|---|
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $318.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | short runway, thin data; fortress balan...<br>not computable: distress |
| **Inputs computable** | 5 of 14 |
| **Graded from** | filings received through Feb 26, 2026<br>255 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026 |
| **Last close** | $1.83<br>2026-11-06; market equity $222.5M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 26, 2026*

We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients. We have pioneered a therapeutic approach that we generally refer to as cellular programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, we generate a clonal master iPSC line for use as a renewable source of starting material for the manufacture of cell therapies; through the manufacturing process, we direct the fate of the clonal master iPSC line to produce our cell th...

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 48.9** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

| | | | | | | |
|---|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | (8.0%) | (6.6%) | | 48.9 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 31.4** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *liabilities and a nearby cover-page share count are required at 2026-09-30* | | | | | | |
| Altman Z double-prime | not computable | (0.37) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *interest expense must exceed $100,000* | | | | | | |
| Current ratio | 5.79x | 2.94x | | 31.4 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 70.8** | | | | | | |
| Revenue growth, three-year compound | (59.0%) | 10.0% | | 96.6 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | (23.3%) | 2.2% | | 87.5 | 696 | 2025-12-31 |
| Net share issuance, one year | 1.5% | 2.5% | | 28.5 | 630 | 2026-02-19 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Short runway | cash runway is 5.0 months |
| Thin data | 5 of 14 grade factors are computable; minimum is 7 |
| Fortress balance sheet | cash minus debt is 172,034,000 USD; Altman Z is not used |

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 75.6% | (2.1%) | 85 |
| Distance from 52-week high | (41.0%) | (30.5%) | 38 |
| EBIT to enterprise value | (74.7%) | (1.5%) | 10 |
| Free cash flow yield | (50.2%) | (1.0%) | 15 |
| Book value to price | 0.60 | 0.29 | 74 |
| Sales to price | 0.03 | 0.30 | 11 |
| Composite equity issuance, five years | 25.9% | 21.4% | 53 |
| Relative strength against the sector, log excess return | 0.40 | (0.19) | 85 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $43.9M |
| Operating cash flow, four quarters | -$105.3M |
| Months of runway | 5.0 |
| Days since last periodic filing | 3 (10-Q received Nov 5, 2026) |
| Median daily dollar volume, 63 sessions | $2.6M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$136.3M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$106.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 3 | assets | us-gaap:Assets | $318.9M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 4 | assets | us-gaap:Assets | $440.7M | 2024-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 5 | total debt | us-gaap:LongTermDebt | $18.5M | 2018-12-31 | 2019-03-05 | 10-K | 19-006258 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $190.5M | 2018-12-31 | 2021-02-24 | 10-K | 21-008086 |
| 7 | operating income | us-gaap:OperatingIncomeLoss | -$67.1M | 2018-12-31 | 2021-02-24 | 10-K | 21-008086 |
| 8 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $1.2M | 2018-12-31 | 2021-02-24 | 10-K | 21-008086 |
| 9 | operating income | us-gaap:OperatingIncomeLoss | -$217.0M | 2021-12-31 | 2023-02-28 | 10-K | 23-005067 |
| 10 | interest expense | us-gaap:InterestExpense | $0 | 2021-12-31 | 2022-02-28 | 10-K | 22-002293 |
| 11 | current assets | us-gaap:AssetsCurrent | $208.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 12 | current liabilities | us-gaap:LiabilitiesCurrent | $36.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 13 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $6.6M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $13.6M | 2024-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $63.5M | 2023-12-31 | 2025-03-05 | 10-K | 25-033510 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $96.3M | 2022-12-31 | 2024-02-26 | 10-K | 24-020158 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $6.0M | 2025-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 18 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$122.9M | 2024-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 19 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $730,000 | 2024-12-31 | 2026-02-26 | 10-K | 26-073699 |
| 20 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$132.3M | 2023-12-31 | 2025-03-05 | 10-K | 25-033510 |
| 21 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $6.2M | 2023-12-31 | 2025-03-05 | 10-K | 25-033510 |
| 22 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$248.2M | 2022-12-31 | 2024-02-26 | 10-K | 24-020158 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $35.6M | 2022-12-31 | 2024-02-26 | 10-K | 24-020158 |
| 24 | assets | us-gaap:Assets | $506.2M | 2023-12-31 | 2025-03-05 | 10-K | 25-033510 |
| 25 | assets | us-gaap:Assets | $705.6M | 2022-12-31 | 2024-02-26 | 10-K | 24-020158 |
| 26 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 116,263,459 | 2026-02-19 | 2026-02-26 | 10-K | 26-073699 |
| 27 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 114,597,425 | 2025-02-25 | 2025-03-05 | 10-K | 25-033510 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.